Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lava Therapeutics N.V. (NQ: LVTX )

1.690 -0.020 (-1.17%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,131
Open 1.670
Bid (Size) 1.630 (2)
Ask (Size) 1.740 (1)
Prev. Close 1.710
Today's Range 1.631 - 1.741
52wk Range 1.131 - 6.470
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024
LVTX stock results show that LAVA Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire

Performance

YTD
-3.59%
-3.59%
1 Month
+5.62%
+5.62%
3 Month
-8.65%
-8.65%
6 Month
-42.71%
-42.71%
1 Year
+20.28%
+20.28%

More News

Read More
LAVA Announces Annual Meeting of Shareholders
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
What 5 Analyst Ratings Have To Say About LAVA Therapeutics
Via Benzinga
LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
Via FinancialNewsMedia
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
From FN Media Group LLC
Via GlobeNewswire
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
From LAVA Therapeutics N.V.
Via GlobeNewswire
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
Via AB Newswire
Topics Retirement
Exposures Pension
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
Via Benzinga
Topics Government
Exposures Political
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Dow Surges Over 100 Points; US GDP Growth Tops Estimates
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Cancer Focused LAVA Therapeutics Nano Cap Stock Trading Higher Today?
Via Benzinga
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
From LAVA Therapeutics N.V.
Via GlobeNewswire
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.